Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 5
  1. Sorafenib or sunitinib. In randomized controlled studies, sorafenib and sunitinib agents have demonstrated an increased response rate, reduced toxicity, and improved survival compared with interferon alfa in patients with renal cell carcinoma.5,6 This patient is not a candidate for high-dose interleukin 2 due to his cardiac and renal dysfunction. Metastasectomy or ablation of metastases may be considered in the future if the patient achieves a good response to systemic therapy. Observation is a less desirable option in this patient, since there has been objective evidence of disease progression over the past 6 months.

    5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med 2007;356:125-34.

    6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj